stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) Total debt
Madrigal Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $339.9M, up 189.1% from $117.6M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $341.3M. Over the past ten years it has ranged from $361.0K (fiscal 2019) to $339.9M (fiscal 2025) — the current reading is the highest in ten years. Madrigal Pharmaceuticals, Inc. ranks 37th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $339.9M | 189.09% |
| FY2024 | $117.6M | 1.81% |
| FY2023 | $115.5M | 134.29% |
| FY2022 | $49.3M | 12,636.18% |
| FY2021 | $387.0K | (17.31%) |
| FY2020 | $468.0K | 29.64% |
| FY2019 | $361.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $341.3M | 0.14% |
| Jun 2026 | $340.8M | 0.14% |
| Mar 2026 | $340.3M | 0.13% |
| Dec 2025 | $339.9M | 0.04% |
| 32 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on MDGL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement